Tags

Type your tag names separated by a space and hit enter

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Neurology. 2003 Dec 09; 61(11 Suppl 6):S55-61.Neur

Abstract

A remarkable convergence of epidemiologic and laboratory data has raised the possibility that caffeine reduces the risk of developing Parkinson's disease (PD) by preventing the degeneration of nigrostriatal dopaminergic neurons. The authors review the evidence that caffeine and more specific antagonists of the adenosine A2A receptor protect dopaminergic neurons in several toxin models of PD. Other studies demonstrating protection by A2A receptor inactivation in animal models of stroke, Huntington's disease, and Alzheimer's disease suggest a more global role of A2A receptors in neuronal injury and degeneration. Although the cellular and molecular mechanisms by which A2A receptors contribute to neuronal death are not yet established, several intriguing possibilities have emerged. Now with preliminary clinical data substantiating the antiparkinsonian symptomatic benefit of A2A receptor blockade, the prospects for a complementary neuroprotective benefit have enhanced the therapeutic potential of A2A antagonists in PD.

Authors+Show Affiliations

Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA. michaels@helix.mgh.harvard.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

14663012

Citation

Schwarzschild, Michael A., et al. "Neuroprotection By Caffeine and More Specific A2A Receptor Antagonists in Animal Models of Parkinson's Disease." Neurology, vol. 61, no. 11 Suppl 6, 2003, pp. S55-61.
Schwarzschild MA, Xu K, Oztas E, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 2003;61(11 Suppl 6):S55-61.
Schwarzschild, M. A., Xu, K., Oztas, E., Petzer, J. P., Castagnoli, K., Castagnoli, N., & Chen, J. F. (2003). Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology, 61(11 Suppl 6), S55-61.
Schwarzschild MA, et al. Neuroprotection By Caffeine and More Specific A2A Receptor Antagonists in Animal Models of Parkinson's Disease. Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. PubMed PMID: 14663012.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. AU - Schwarzschild,Michael A, AU - Xu,Kui, AU - Oztas,Emin, AU - Petzer,Jacobus P, AU - Castagnoli,Kay, AU - Castagnoli,Neal,Jr AU - Chen,Jiang-Fan, PY - 2003/12/10/pubmed PY - 2004/2/12/medline PY - 2003/12/10/entrez SP - S55 EP - 61 JF - Neurology JO - Neurology VL - 61 IS - 11 Suppl 6 N2 - A remarkable convergence of epidemiologic and laboratory data has raised the possibility that caffeine reduces the risk of developing Parkinson's disease (PD) by preventing the degeneration of nigrostriatal dopaminergic neurons. The authors review the evidence that caffeine and more specific antagonists of the adenosine A2A receptor protect dopaminergic neurons in several toxin models of PD. Other studies demonstrating protection by A2A receptor inactivation in animal models of stroke, Huntington's disease, and Alzheimer's disease suggest a more global role of A2A receptors in neuronal injury and degeneration. Although the cellular and molecular mechanisms by which A2A receptors contribute to neuronal death are not yet established, several intriguing possibilities have emerged. Now with preliminary clinical data substantiating the antiparkinsonian symptomatic benefit of A2A receptor blockade, the prospects for a complementary neuroprotective benefit have enhanced the therapeutic potential of A2A antagonists in PD. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/14663012/Neuroprotection_by_caffeine_and_more_specific_A2A_receptor_antagonists_in_animal_models_of_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -